GAMIDA CELL LTD (GMDA) Stock Price, Forecast & Analysis
USA - NASDAQ:GMDA - IL0011552663 - Common Stock
GMDA Key Statistics, Chart & Performance
The current stock price of GMDA is 0.0327 USD. In the past month the price decreased by -90.3%. In the past year, price decreased by -95.57%.
GMDA Latest News, Press Relases and Analysis
GMDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About GMDA
Company Profile
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Company Info
GAMIDA CELL LTD
PO Box 34670
JERUSALEM 95484 IL
CEO: Julian Adams
Employees: 143
Phone: 97226595666
GAMIDA CELL LTD / GMDA FAQ
Can you describe the business of GAMIDA CELL LTD?
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The firm is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
What is the current price of GMDA stock?
The current stock price of GMDA is 0.0327 USD. The price decreased by -18.25% in the last trading session.
What is the dividend status of GAMIDA CELL LTD?
GMDA does not pay a dividend.
How is the ChartMill rating for GAMIDA CELL LTD?
GMDA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for GAMIDA CELL LTD?
GAMIDA CELL LTD (GMDA) operates in the Health Care sector and the Biotechnology industry.
Would investing in GAMIDA CELL LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GMDA.
What is the market capitalization of GMDA stock?
GAMIDA CELL LTD (GMDA) has a market capitalization of 4.34M USD. This makes GMDA a Nano Cap stock.
GMDA Technical Analysis
GMDA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GMDA. GMDA may be in some trouble as it scores bad on both profitability and health.
GMDA Financial Highlights
Over the last trailing twelve months GMDA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 49.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GMDA Forecast & Estimates
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
For the next year, analysts expect an EPS growth of 9.37% and a revenue growth 808.75% for GMDA